(RTTNews) – INOVIO (INO) introduced promising interim outcomes from an ongoing Section 1 proof-of-concept trial evaluating DNA-Encoded Monoclonal Antibodies or DMAbs for COVID-19.
Within the trial, 100% (24/24) of individuals who’ve reached week 72 maintained biologically related ranges of DMAbs, confirming the sturdiness of in vivo antibody manufacturing. Notably, no participant developed anti-drug antibodies (ADA), a standard problem noticed in different gene-based supply platforms, akin to adeno-associated virus (AAV) mediated antibody expression, the corporate mentioned.
As well as, the corporate famous that the DMAbs had been nicely tolerated, with the most typical unwanted effects being gentle, momentary injection website reactions, akin to ache and redness.
The trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and scientific investigators on the Perelman College of Drugs on the College of Pennsylvania.
The consortium plans to current interim outcomes from the trial at upcoming scientific conferences in 2025.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
Reference :
https://www.nasdaq.com/articles/inovio-announces-promising-interim-results-phase-1-proof-concept-trial-dmabs-covid-19